Cargando…

Serum insulin‐like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma‐associated malnutrition and muscle wasting

BACKGROUND: Malnutrition and muscle wasting are common features frequently observed in pancreatic ductal adenocarcinoma (PDAC) patients with cancer cachexia. They are associated with reduced survival and quality of life. Nutrition therapy is an important part of multimodal cancer care in PDAC. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Jie, Yu, Jie, Li, Zekun, Gao, Song, Wang, Hongwei, Yang, Shengyu, Wu, Liangliang, Lan, Chungen, Zhao, Tiansuo, Gao, Chuntao, Liu, Zhe, Wang, Xiuchao, Hao, Jihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200427/ https://www.ncbi.nlm.nih.gov/pubmed/33763996 http://dx.doi.org/10.1002/jcsm.12692

Ejemplares similares

SCF, Regulated by HIF-1α, Promotes Pancreatic Ductal Adenocarcinoma Cell Progression
por: Gao, Chuntao, et al.
Publicado: (2015)

Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes
por: Wang, Xiuchao, et al.
Publicado: (2016)

Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I–III pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Zou, Yiping, et al.
Publicado: (2023)

Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma
por: Liu, Jing, et al.
Publicado: (2019)

ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour–stromal IL-1β/NF–κB/ESE3 signalling axis
por: Zhao, Tiansuo, et al.
Publicado: (2022)

Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression
por: Huang, Chongbiao, et al.
Publicado: (2017)

Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma
por: Li, Xiaojie, et al.
Publicado: (2020)

Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma
por: Ni, Bo, et al.
Publicado: (2023)

Preoperative ultrasound combined with routine blood tests in predicting the malignant risk of pancreatic cystic neoplasms
por: Wang, Xiuchao, et al.
Publicado: (2022)

Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
por: Zhao, Tiansuo, et al.
Publicado: (2014)

IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer
por: Zhao, Tiansuo, et al.
Publicado: (2020)

Hypoxia-Inducible Factor-1α Regulates Chemotactic Migration of Pancreatic Ductal Adenocarcinoma Cells through Directly Transactivating the CX3CR1 Gene
por: Zhao, Tiansuo, et al.
Publicado: (2012)

Correction: Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
por: Zhao, Tiansuo, et al.
Publicado: (2019)

An Integrative Pan-Cancer Analysis Revealing MLN4924 (Pevonedistat) as a Potential Therapeutic Agent Targeting Skp2 in YAP-Driven Cancers
por: Lan, Chungen, et al.
Publicado: (2022)

PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC
por: Wang, Xiuchao, et al.
Publicado: (2020)

Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma
por: Fu, Danqi, et al.
Publicado: (2023)

A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms
por: Lan, Chungen, et al.
Publicado: (2018)

CypA, a Gene Downstream of HIF-1α, Promotes the Development of PDAC
por: Zhang, Huan, et al.
Publicado: (2014)

Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
por: Li, Haorui, et al.
Publicado: (2023)

BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis
por: Huang, Chongbiao, et al.
Publicado: (2023)

OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma
por: Ding, Jinsheng, et al.
Publicado: (2021)

Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression
por: Jin, Fanjie, et al.
Publicado: (2020)

MicroRNA-608 promotes apoptosis via BRD4 downregulation in pancreatic ductal adenocarcinoma
por: Li, Maoyuan, et al.
Publicado: (2020)

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
por: Li, Tianjiao, et al.
Publicado: (2019)

A new staging system for postoperative prognostication in pancreatic ductal adenocarcinoma
por: Liang, Yuexiang, et al.
Publicado: (2023)

Detection of Circulating Tumor Cells Using Negative Enrichment Immunofluorescence and an In Situ Hybridization System in Pancreatic Cancer
por: Xu, Yu, et al.
Publicado: (2017)

Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer
por: Li, Shengnan, et al.
Publicado: (2022)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma
por: Li, Shuo, et al.
Publicado: (2019)

Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma
por: Chen, Dongjie, et al.
Publicado: (2021)

Integrated single-cell multiomics analysis reveals novel candidate markers for prognosis in human pancreatic ductal adenocarcinoma
por: Fan, Xiaoying, et al.
Publicado: (2022)

Methylation of CALCA and CALCB in Pancreatic Ductal Adenocarcinoma
por: Gao, Feng, et al.
Publicado: (2021)

Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis
por: Zhou, Tianxing, et al.
Publicado: (2023)

Prognostic value of γ‐glutamyltransferase‐to‐albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery
por: Li, Shuo, et al.
Publicado: (2019)

Combination of RUNX1 inhibitor and gemcitabine mitigates chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress
por: She, Chunhua, et al.
Publicado: (2023)

Expression of Notch receptors and their ligands in pancreatic ductal adenocarcinoma
por: Song, Hai-Yan, et al.
Publicado: (2018)

Expression and clinical significance of HSPA2 in pancreatic ductal adenocarcinoma
por: Zhang, Hui, et al.
Publicado: (2015)

The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids
por: Low, Ronnie Ren Jie, et al.
Publicado: (2021)

Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma
por: Gao, He-Li, et al.
Publicado: (2020)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lc1debfsismust11rssddm59li